Skip to main content

Table 2 Change from baseline to Week 12 in SF-36 bodily pain, social functioning, and role-physical domains in eptinezumab-treated ≥ 75% and ≥ 50–< 75% migraine responders

From: Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials

  Eptinezumab 100 mg Eptinezumab 300 mg Eptinezumab Pooled
PROMISE-1 (EM) ≥ 50–< 75%
N = 61
≥ 75%
N = 49
≥ 50–< 75%
N = 59
≥ 75%
N = 66
≥ 50–< 75%
N = 120
≥ 75%
N = 115
Bodily pain
 Baseline, mean (SD) 45.8 (8.88) 46.2 (9.95) 46.5 (9.71) 48.5 (9.30) 46.1 (9.27) 47.5 (9.60)
 Week 12, mean (SD) 51.2 (8.99) 52.7 (8.26) 52.5 (7.86) 54.7 (7.20) 51.8 (8.46) 53.9 (7.70)
 Change from baseline, mean (SD) 5.8 (8.24) 6.7 (7.83) 6.1 (8.19) 5.9 (7.66) 5.9 (8.18) 6.2 (7.71)
Social functioning
 Baseline, mean (SD) 48.6 (9.37) 50.6 (8.22) 50.4 (8.98) 51.4 (8.06) 49.5 (9.19) 51.1 (8.10)
 Week 12, mean (SD) 51.5 (8.97) 53.9 (5.08) 52.8 (6.97) 53.9 (6.26) 52.1 (8.07) 53.9 (5.77)
 Change from baseline, mean (SD) 3.3 (9.96) 3.2 (7.49) 2.6 (8.26) 2.2 (7.14) 3.0 (9.15) 2.6 (7.28)
Role-physical
 Baseline, mean (SD) 49.8 (7.61) 49.1 (8.90) 49.7 (7.75) 50.1 (7.91) 49.8 (7.64) 49.7 (8.32)
 Week 12, mean (SD) 51.2 (6.92) 53.8 (6.57) 52.8 (5.71) 54.2 (5.04) 52.0 (6.39) 54.0 (5.72)
 Change from baseline, mean (SD) 1.5 (7.86) 4.7 (7.91) 3.1 (6.56) 3.9 (7.50) 2.3 (7.28) 4.3 (7.65)
PROMISE-2 (CM) ≥ 50–< 75%
N = 110
≥ 75%
N = 95
≥ 50–< 75%
N = 99
≥ 75%
N = 116
≥ 50–< 75%
N = 209
≥ 75%
N = 211
Bodily pain
 Baseline, mean (SD) 40.6 (10.25) 40.1 (9.60) 40.5 (8.97) 40.1 (9.40) 40.5 (9.64) 40.1 (9.47)
 Week 12, mean (SD) 45.8 (8.81) 49.2 (8.14) 46.8 (7.80) 50.2 (7.57) 46.3 (8.35) 49.7 (7.82)
 Change from baseline, mean (SD) 5.1 (8.22) 9.4 (9.66) 6.2 (8.37) 10.1 (9.21) 5.6 (8.29) 9.8 (9.39)
Social functioning
 Baseline, mean (SD) 43.7 (9.36) 42.6 (10.82) 44.0 (10.05) 43.0 (9.65) 43.8 (9.67) 42.8 (10.17)
 Week 12, mean (SD) 49.1 (7.42) 51.1 (6.83) 49.0 (7.48) 51.1 (7.42) 49.1 (7.43) 51.1 (7.15)
 Change from baseline, mean (SD) 5.3 (7.41) 8.4 (9.50) 5.5 (7.68) 8.0 (9.14) 5.4 (7.52) 8.2 (9.28)
Role-physical
 Baseline, mean (SD) 42.5 (8.52) 42.3 (9.04) 42.4 (9.15) 42.2 (8.72) 42.4 (8.80) 42.2 (8.84)
 Week 12, mean (SD) 48.1 (7.61) 49.4 (6.79) 48.7 (7.51) 50.7 (6.93) 48.4 (7.55) 50.1 (6.88)
 Change from baseline, mean (SD) 5.5 (7.05) 7.1 (9.74) 6.5 (7.74) 8.6 (8.67) 6.0 (7.38) 7.9 (9.17)
  1. A ≥ 75% or ≥ 50–< 75% migraine responder was defined as a patient who achieved a ≥ 75% or ≥ 50–< 75% reduction in mean monthly migraine days over Weeks 1–12. CM, chronic migraine; EM, episodic migraine; SD, standard deviation; SF-36, 36-item Short-Form Health Survey (v2.0)